Med Ed Report briefs—March 2012

FDA commissioner Margaret Hamburg told a House committee in February that FDA conflict of interest (COI) rules do not need to be relaxed. Hamburg cited FDA data showing that the percentage of COI waivers and advisory committee vacancies has stayed low.

Med-IQ, an accredited CME provider, said its performance-improvement CME initiative in multiple sclerosis was approved as part of the American Board of Psychiatry and Neurology's maintenance-of-certification program.

The American Medical Student Association will launch its 2011-2012 PharmFree Scorecard on March 8 as part of its Annual Convention in Houston.

Pharma companies dedicate 1.9% of their med-ed FTEs and budget to the Asia-emerging areas, while device companies allocate 7.5% of their med-ed FTEs and 6.4% of their med-ed budget to these areas, according to research by Best Practices, LLC.

The American College of Physicians (ACP) and CECity are using a pilot among diabetic patients in ACP state chapters to test the ability of CECity's cloud-based MedConcert to improve patient-care processes and outcomes.
You must be a registered member of MMM to post a comment.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.